NCT03991442View on ClinicalTrials.gov

BR1010 in Patients With Essential Hypertension Patients Who do Not Adequately Respond to Fimasartan/Amlodipine Combination

PHASE3CompletedINTERVENTIONAL
Enrollment

257

Participants

Timeline

Start Date

June 17, 2019

Primary Completion Date

March 2, 2021

Study Completion Date

March 2, 2021

Conditions
Essential Hypertension
Interventions
DRUG

Fimasartan/Amlodipine

Active Comparator: a fixed dose combination of Fimasartan/Amlodipine or placebo

Trial Locations (1)

Unknown

Boryung Pharmaceutical Co., Ltd, Seoul

Sponsors
All Listed Sponsors
lead

Boryung Pharmaceutical Co., Ltd

INDUSTRY